Glaukos Corporation – the ophthalmic medical technology and pharmaceutical company that pioneered micro-invasive glaucoma surgery – has completed its previously announced acquisition of Avedro, Inc.
Today marks an important day for Glaukos as Avedro will serve as the cornerstone of our new corneal health franchise,” said Thomas Burns, Glaukos president and chief executive officer. “This transaction pairs two highly complementary, hybrid pharma and device organisations, combining Avedro’s novel bio-activated pharmaceutical solutions and R&D capabilities with Glaukos’ global commercial scale, proven market-building and shared reimbursement expertise, and extensive clinical and regulatory infrastructure.
This transaction pairs two highly complementary, hybrid pharma and device organisations
“We’re excited to welcome the talented Avedro employees to the Glaukos organisation to help build upon our solid foundation to transform Glaukos into a global ophthalmic pharmaceutical and device leader capable of serving the vision care needs of physicians and their patients for years to come.”